Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
113.3 USD | -8.21% | -12.23% | +17.53% |
May. 28 | Sarepta Therapeutics Shares Fall After RBC Downgrade | MT |
May. 28 | RBC Downgrades Sarepta Therapeutics to Sector Perform From Outperform, Lowers Price Target to $142 From $157 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The firm trades with high earnings multiples: 35.03 times its 2024 earnings per share.
- With an enterprise value anticipated at 5.02 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+17.53% | 10.71B | C+ | ||
+9.83% | 115B | B+ | ||
+10.80% | 105B | B+ | ||
-10.84% | 22.71B | B+ | ||
-1.83% | 21.83B | B | ||
-10.86% | 18.18B | A- | ||
-41.92% | 16.52B | A- | ||
-15.11% | 16.01B | B | ||
+6.62% | 14.14B | C+ | ||
-30.73% | 7.6B | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SRPT Stock
- Ratings Sarepta Therapeutics, Inc.